BioCentury
ARTICLE | Company News

Mylan, GlaxoSmithKline neurology news

March 31, 2014 7:00 AM UTC

In Mylan Inc. et al v. SmithKline Beecham Corp. et al, a jury in the U.S. District Court for the District of New Jersey awarded Mylan $106.7 million in damages from GlaxoSmithKline after ruling that GSK breached a 2007 contract with Mylan for the commercialization of a generic version of an extended-release formulation of neurology drug Paxil paroxetine. According to Mylan's 2010 complaint, under a 2007 agreement with GSK, Mylan had the exclusive right to sell the generic formulation, but in 2010 GSK allowed Apotex Inc. (Toronto, Ontario) to sell an authorized generic version of the product.

Mylan said it is pleased with the verdict and "intends to seek additional relief to further protect its rights," but declined to provide additional comment. GSK said it is "disappointed in the outcome and are considering all options." ...